| |
 |
Jackie Fairley, BSc, BVSc (Hons), MBA
Chief Executive Officer
Dr Fairley has over 15 years' experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Mayne Pharma). Prior to joining Starpharma as COO in 2005, she was CEO of Cerylid Biosciences Limited. During her time as CEO of Cerylid, the company generated revenues of over $20 million, raised more than $10 million private equity funding and completed the acquisition and integration of a private kinase company. Prior to joining the biotechnology sector, Dr Fairley spent 5 years as a Vice President for Faulding's injectable division where she was responsible for the group's global business development activities and injectable development program supporting product sales of > $200 million into 70 countries. She is a member of the Federal Government's Pharmaceutical Industry Working Group, and the Victorian Innovation Economy Advisory Board. |
 |
Paul Barrett, BSc (Hons), PhD
Vice President, Business Development
Dr Barrett has 6 years' experience in marketing and business development gained in both start-up and multinational technology companies in the UK. He has also ran a competitive intelligence unit providing strategic and tactical direction in sales planning. As a research scientist he has worked in academia and industry, including at the Department of Biochemistry, University of Oxford, where he published in the areas of cell-cycle kinase function, drug design, and structural bioinformatics. He has publications in photonics and in classical lens design and is the co-inventor on a patent for a communications device. |
 |
Dr David Owen
Vice President, Research
Dr David Owen has extensive experience in medicinal chemistry, biochemistry and managing teams focussed on commercially directed drug discovery. He has held several positions in the biotech industry starting out with Mimotopes (part of Mitokor Inc.) as a senior chemist, he worked on projects for several major pharmaceutical companies. He then joined Cerylid as Head of Chemistry, and following that took on the same position at Glykoz, where he headed up a team of chemists working on a new class of antibacterial agents. David has expertise in a wide range of areas of chemistry including the synthesis of natural products, peptides, carbohydrates and heterocyclic compounds and has worked across a range of therapeutic areas including type 2 diabetes, antimicrobials and anticancer agents.
David has a First Class honours in Chemistry from the University of Queensland and has a PhD from the Australian National University. Following his PhD he went on to work with a number of internationally recognized academic research groups taking on post doctoral fellowships at the University of Utah, USA, a prestigious Alexander von Humboldt Fellowship at the University of Karlsruhe, Germany and an ARC postdoctoral fellowship at the Victorian College of Pharmacy, Monash University working with Professor Mark Von Izstein. David is a co-author on 20 publications and 5 patents. |
 |
Jeremy Paull, BSc (Hons), PhD
Vice President, Development and Regulatory Affairs
Dr Paull is responsible for managing Starpharma's regulatory and clinical affairs. Jeremy received a PhD in Pharmacology from Monash University, in 2000 for work on the functional and structural cardiovascular effects of various antihypertensive drugs. Prior to joining Starpharma, he worked with the Australian biotechnology company, Norwood Abbey, on the development of a medical device which was approved to alter skin properties and improve transdermal drug delivery. Since joining Starpharma in 2001, Dr Paull's efforts have been integral to the implementation of the company's quality management system (QMS), the preparation and submission of Starpharma's first Investigational New Drug (IND) application to the US Food & Drug Administration (FDA), and the advancement of the clinical aspects of the VivaGel™ development program. He has overseen expansion of the QMS and now directs the company's regulatory and clinical strategy. |
 |
Ben Rogers
Company Secretary
Mr Rogers has extensive experience in finance and human resources management with the CSIRO research laboratories in Victoria, South Australia, and Western Australia. He also operated his own consulting business providing services to Co-operative Research Centres and CSIRO Divisions. Mr Rogers joined Starpharma on commencement of operations in April 1997 and was appointed to the position of Company Secretary in February 1998. He is a member of the senior executive team with responsibilities that include the role of Chief Financial Officer. |
 |
Nigel Baade, BCom, CPA, Grad Dip Arts (Development)
Financial Controller
Mr Baade is a CPA qualified accountant with experience in the pharmaceutical and biotechnology industries. His previous roles have included Finance Manager of Cerylid Biosciences and Manager Accounting, International Business Development for Faulding (now Symbion Health or Mayne Pharma). Mr Baade has extensive experience in financial control, project and cost management of research activities, the commercialisation of global business development opportunities, private equity raising and grant funding. Prior to joining Starpharma in January 2006, he held a commercial planning role with Dutch multinational, Hagemeyer. He has a Postgraduate Diploma in International Development from Monash University. |
|  |
|
